基于风险的选择治疗策略在肝细胞癌与大血管入侵的肝细胞癌
Nalee Kim1, Hyunki Park1, Jeong Il Yu1
1Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
这项研究表明,一种新的风险分层模型有效指导肝细胞癌 (HCC) 与宏血管侵入 (MVI) 的治疗选择. 该模型有助于个性化TACE+RT或阿特佐利祖马布/贝瓦西祖马布+RT等疗法,以获得更好的患者结果.
科学领域:
- 肝胆瘤学 肝胆瘤学
- 癌症治疗方法 癌症治疗方法
- 临床研究 临床研究
背景情况:
- 肝细胞癌 (HCC) 与宏血管入侵 (MVI) 呈现出复杂的管理挑战,由于其多样化的临床行为.
- 目前对MVI的HCC的治疗策略包括跨动脉化学栓塞 (TACE) 加放射治疗 (RT),氨酸激酶抑制剂 (TKIs) 加RT,以及具有或没有RT的阿特佐利祖马布/贝瓦西祖马布 (AB).
研究的目的:
- 评估不同治疗策略的有效性和安全性,用于MVIHCC.
- 评估之前提出的MVI风险分层模型在指导治疗决策中的有用性.
主要方法:
- 对526名 MVI 患者的先前未接受治疗的 HCC 患者进行了回顾性分析.
- 根据MVI分类,患者被分为非常低风险/低风险和中等风险/高风险组.
- 使用卡普兰-梅尔和考克斯回归分析了生存结果 (IPFS,EPFS,PFS,OS).
主要成果:
- MVI风险分层与所有生存结果有显著的相关性.
- 在极低/低风险组中,TACE+RT的表现优于TKI+RT.
- 在中等/高风险组中,AB + RT与TACE + RT或单独AB相比显示出更好的生存率.
- TKI + RT 与肝功能恶化的最高频率有关.
结论:
- 拟议的MVI风险分层模型有效地区分了HCC与MVI的预后.
- 这种模型可以作为优化治疗选择的宝贵工具.
- 需要进行前性研究来验证这种风险分层的临床实用性.
更多相关视频
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
相关概念视频
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Venous Thrombosis III: Interprofessional Care
